Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV (p)

1709.00

Share Price (p)

1664.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 154.67%
Worldwide Healthcare (Ordinary Share) NAV 143.61%
FTSE World 58.26%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1663.0p -2.7% 1709.00p 1718.00p
19 Nov
111% 0.90%

Discrete performance % over

Fund / BenchmarkDec '11
Nov '12
Dec '12
Nov '13
Dec '13
Nov '14
Worldwide Healthcare (Ordinary Share) Price22.8646.5841.41
Worldwide Healthcare (Ordinary Share) NAV21.8042.9539.92
FTSE World12.6725.3112.09

Discrete performance over

Discrete Performance

Top 10 Holdings

Bristol-Myers Squibb Company 3.90%
Roche Holding AG 3.70%
Regeneron Pharmaceuticals, Inc. 3.70%
HCA Holdings Inc 3.70%
Gilead Sciences Inc 3.60%
Amgen Inc 3.50%
Biogen Idec Inc., 3.20%
Merck & Co. Inc. 3.00%
Intuitive Surgical, Inc. 2.90%
ONO Pharmaceutical Co., Ltd. 2.70%

Sectors weighting

Pharmaceuticals 98.20%
Fixed Interest 4.10%
Net Current Assets -2.30%

Regional weighting

North America Region 73.00%
Europe Developed ex-UK 11.00%
Japan 8.00%
Fixed Interest 4.00%
Other Countries 3.00%
Asia exc Japan 2.00%
UK 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Base Currency GBX
  • Domicile UK
  • Share Price (p) 1664.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 48
  • Market Capital (£M) 799.85
  • Gross Assets (£M) 913.52
  • Net Assets (£M) 822.13
  • TER (%) 0.73
  • Historic Dividend Yield (%) 0.90
  • Last AGM 24 Jul 2014
  • Next AGM 24 Jul 2015
  • Last Annual Report Date 16 Jun 2014
  • Next due Report Date  
  • Next due Report Type I/R
  • Objective:

  • To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel. D Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to GBP150m, 0.20% p.a. of the market capitalisation in excess of GBP150m and up to GBP500m, and 0.125% p.a. of the market capitalisation in excess of GBP500m, plus a fixed amount equal to GBP 57,500 per annum. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any out-performance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.